The international surgical journal with global reach

Efficacy and safety of the duodeno-jejunal bypass liner in patients with metabolic syndrome. A multicenter randomized controlled trial (ENDOMETAB). Ann Surg 2020; 272: 696-702.

Published: 9th February 2021

Authors: Caiazzo R, Branche J, Raverdy V, Czernichow S, Carette C, Robert M et al.

Conclusion

This study compared standard care with endoscopic insertion of the liner in 82 patients. After one year, remission of the metabolic syndrome occurred in 12 per cent compared to 10 per cent in controls (P=0.72). Patients who had the liner lost more weight in the first 12 months, but weight in both groups was similar 12 months after the liner was removed.

Pubmed Link